Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.95 USD
Change Today 0.00 / 0.00%
Volume 0.0
GEDSF On Other Exchanges
As of 4:30 PM 02/25/15 All times are local (Market data is delayed by at least 15 minutes).

richter gedeon -spons gdr (GEDSF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $16.00
52 Week Low
02/25/15 - $14.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

richter gedeon -spons gdr (GEDSF) Related Businessweek News

No Related Businessweek News Found

richter gedeon -spons gdr (GEDSF) Details

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. engages in the research, development, manufacture, sale, and marketing of pharmaceutical products in Hungary, the European Union, the Commonwealth of Independent States, the United States, China, Latin America, and internationally. It operates through Pharmaceuticals, and Wholesale and Retail segments. The company develops products for various therapeutic areas, including gynaecology, cardiovascular, gastrointestinal, central nervous system, muscle relaxants, and others. Its gynecological products include contraceptives, emergency contraceptives, hormone replacements, fungicides, and preparations used for the treatment of uterine fibroids; and contraceptive devices, as well as products for menopausal care, pregnancy care and obstetrics, gynaecological infections, and other gynaecological conditions; and central nervous system products comprise products for the treatment of chronic cerebral circulatory disorders, anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as a product for the treatment of neuropathic pain. The company also offers products for the prevention and treatment of various cardiovascular diseases. In addition, it produces various over-the-counter pharmaceutical products for various health problems, including Escapelle (Postinor), an emergency contraceptive pill; Panangin for supporting cardiovascular health; Stopdiar to treat diarrhea; Lordestin and Zilola for allergy; and Curiosin for wound care. Further, the company operates 108 pharmacy units. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary.

11,525 Employees
Last Reported Date: 05/6/15
Founded in 1901

richter gedeon -spons gdr (GEDSF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

richter gedeon -spons gdr (GEDSF) Key Developments

European Commission Approves Gedeon Richter's Esmya® 5 Mg for Intermittent Treatment in the Long Term Management of Uterine Fibroids (Myomas)

Gedeon Richter plc announced that the European Commission (EC) has granted approval for the intermittent use of Esmya 5 mg in the long term management of uterine fibroids. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 April 2015 and is applicable for all Member States in the European Economic Area. The initial Marketing Authorization for Esmya® was granted for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The present extension of indication adding the intermittent treatment courses of Esmya provides an opportunity to women to benefit from long term medical management of uterine fibroids and potentially avoid surgery. The approval is based on the assessment of two long-term Phase III studies, PEARL III extension and PEARL IV, involving 132 and 451 patients respectively, both designed to evaluate the efficacy and safety of ulipristal acetate as a long-term treatment of uterine fibroids: PEARL III Study and its extension assessed the efficacy and safety of ulipristal acetate 10 mg over a total of 4 intermittent 3-month treatment courses. PEARL IV Study assessed the efficacy and safety of ulipristal acetate 5 and 10 mg over a total of 4 intermittent 3-month treatment courses. Both studies confirmed the efficacy and safety of intermittent use of ulipristal acetate. Efficacy was demonstrated by a reduction of bleeding, fibroid volume and pain and ultimately an improvement in the quality of life of women suffering from symptomatic uterine fibroids. The results of the PEARL IV study demonstrated that 70% of the patients on the 5 mg dose were in amenorrhea after the fourth treatment course. In addition, fibroid volume reduction from baseline was on average 71.8% and uterine volume decreased significantly during the study. Furthermore, the use of ulipristal acetate showed an improvement in quality of life and control of pain in comparison to baseline, even during the off treatment intervals. These results confirmed already published data from the PEARL III and PEARL IV Part 1 studies.

Gedeon Richter plc Announces Executive Changes

Gedeon Richter Plc announced that the company's board of directors notifies its shareholders about the decease of Mr. Sándor Kováts Commercial Director of the company. With effect from 1 July 2015 Mr. Endre Pokomándi will be appointed as the company's Commercial Director. During the interim period Mr. Erik Bogsch, Managing Director will supervise the company's commercial activities.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Provides Tax Guidance for the Full Year 2015

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of HUF 87,675 million compared with HUF 88,304 million for the same period a year ago. Profit from operations was HUF 13,850 million compared with HUF 10,123 million for the same period a year ago. Net financial income was HUF 2,262 million compared with net financial loss of HUF 1,149 million for the same period a year ago. Profit before income tax was HUF 16,411 million compared with HUF 9,627 million for the same period a year ago. Profit attributable to owners of the parent was HUF 15,044 million or HUF 81 per basic and diluted share compared with HUF 9,342 million or HUF 50 per basic and diluted share for the same period a year ago. Net cash flow from operating activities was HUF 16,176 million compared with HUF 15,870 million for the same period a year ago. Payments for property, plant and equipment was HUF 2,199 million compared with HUF 4,415 million for the same period a year ago. Payments for intangible assets was HUF 1,105 million compared with HUF 1,053 million for the same period a year ago. The company's financial results continued to be affected by negative currency exchange effects associated with the weak Russian rouble as well as the devaluation of the Ukrainian hryvnia. The company's slightly disappointing sales figures, albeit with an actual sales increase in Russia, are offset by its very impressive net income figure for the quarter. This reflects a reduction in costs (for sales and marketing as well as research and development) along with a significant rise in net financial income. Nevertheless, the company expects that this kind of tax liability will amount during 2015 to a similar level to that paid in 2014. The company expects to offset the tax payable on this ground by 90% of the tax liability of the same kind incurred during 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEDSF:US $14.95 USD 0.00

GEDSF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.132.50 CHF +1.00
Dr Reddy's Laboratories Ltd 3,428 INR -45.70
Impax Laboratories Inc $50.12 USD +0.50
Pharmstandard OJSC 1,055 RUB 0.00
Medicines Co/The $28.79 USD +0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation GEDSF Industry Range
Price/Earnings 27.9x
Price/Sales 2.4x
Price/Book 1.5x
Price/Cash Flow 27.9x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RICHTER GEDEON -SPONS GDR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at